在线英语听力室_免费在线英语听力学习网站

Global Trade in Fake Drugs Tops $30 Billion

Some 40 percent of the drugs available in many sub-Saharan African and South American countries are either fake or substandard - according to research by the World Bank and international public health groups. And experts say the widespread circulation of poor-quality or substandard medicines leads to frequent treatment failure and even loss of life. 

Experts working to stop this counterfeit¹ drug traffic met in Washington recently to discuss legal and enforcement solutions. Louise Shelley is a criminologist and director of the Terrorism, Transnational Crime and Corruption² Center at George Mason University in Virginia.

“We are focusing much more on narcotics³ trafficking rather than on counterfeits⁴ that can do harm to many more individuals than consuming of illicit⁵ drugs," said Shelley.

Shelley says sophisticated transnational criminal organizations are behind the manufacture and distribution of drugs that do not conform to proper standards. She says only a coordinated⁶ international effort can deal with organized crime on this scale.

“I think WHO, law enforcement community, consumer organizations, civil society everybody has a role in it," she said.

“You have no guarantee of the safety, efficacy or quality of those products," said Margaret Hamburg.

Dr. Margaret Hamburg heads the Food and Drug Administration, the federal agency which oversees⁷ the safety of drugs and food products in the United States. The FDA took strong action this week against thousands of internet pharmacies⁸ selling illegal medical products.

Dr. Patrick Lukulay of The United States Pharmacopeia, an organization that sets standards for medicines, says drug purity needs to be ensured through an international initiative, because the ingredients come from many parts of the world.

“In the US - 80 percent of active ingredients come from either India or China into the US so US companies are vulnerable," said Lukulay.

“In India you have 10,000 manufacturing companies and so although the regulators are making investments it’s difficult to catch up," said Andreas Seiter.

Andreas Seiter is a global pharmaceutical⁹ expert. He says many countries need to increase their regulatory capabilities¹⁰.

And Michael Bates of the World Health Organization says it is not only patients who are ignorant about fake medicines. He says many health professionals are also unaware¹¹.

“This is a complex international trade. And we need greater information on the scale and the scope, the harm and economic damage done by this issue to convince the policy makers¹² to commit resources to tackle this," said Bates.

Experts say a worldwide, coordinated effort is needed to deal with the problem - including better monitoring and regulation, upgrades in law enforcement capabilities, and the sharing of testing technology.